期刊
NEUROPHARMACOLOGY
卷 62, 期 3, 页码 1204-1220出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2011.04.025
关键词
Mouse; Genes; Cognition; Behavior; Schizophrenia
资金
- NIH, NIMH
- Italian Institute of Technology
- Marie Curie FP7-Reintegration-Grant [268247]
Cognitive dysfunction is a core feature of schizophrenia. Growing evidence indicates that a wide variety of genetic mutations and polymorphisms impact cognition and may thus be implicated in various aspects of this mental disorder. Despite differences between human and rodent brain structure and function, genetic mouse models have contributed critical information about brain mechanisms involved in cognitive processes. Here, we summarize discoveries of genetic modifications in mice that impact cognition. Based on functional hypotheses, gene modifications within five model systems are described: 1) dopamine (D1, D2, D3, D4, D5, DAT, COMT, MAO); 2) glutamate (GluR-A, NR1, NR2A, NUB, GRM2, GRM3, GLAST); 3) GABA (alpha(5), gamma(2), alpha(4), delta GABA(A), GABA(B(1)), GAT1); 4) acetylcholine (nAChR beta 2, alpha 7, CHRM1); and 5) calcium (CaMKII-alpha, neurogranin, CaMKK beta, CaMKIV). We also consider other risk-associated genes for schizophrenia such as dysbindin (DTNBP1), neuregulin (NRG1), disrupted-in-schizophrenia1 (DISCI), reelin and proline dehydrogenase (PRODH). Because of the presumed importance of environmental factors, we further consider genetic modifications within the stress-sensitive systems of corticotropin-releasing factor (CRF), brain-derived neurotrophic factor (BDNF) and the endocannabinoid systems. We highlight the missing information and limitations of cognitive assays in genetically modified mice models relevant to schizophrenia pathology. This article is part of a Special Issue entitled 'Schizophrenia' (C) 2011 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据